Examination of the cost-effectiveness of rasagiline versus other approved first-line Parkinson disease therapies indicated that rasagiline was either cost saving or cost-effective in all cases.
Marcy L. Tarrants, PhD, MPA
Advertisement
Articles by Marcy L. Tarrants, PhD, MPA
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Rasagiline Compared With First-Line Early Parkinson Disease Therapies
Published: June 9th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
5
